A citation-based method for searching scientific literature


List of co-cited articles
19 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
75

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
284
50



Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
230
50


Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni, Rosa Maria Bruno. Cardiovasc Diabetol 2017
130
50

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V Karg, Peter Bramlage, Roland E Schmieder. Cardiovasc Diabetol 2017
60
50



Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.
Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
55
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50




Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
856
50

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
535
50


Sympathetic activity and markers of cardiovascular risk in nondiabetic severely obese patients: the effect of the initial 10% weight loss.
Elisabeth A Lambert, Toni Rice, Nina Eikelis, Nora E Straznicky, Gavin W Lambert, Geoffrey A Head, Chris Hensman, Markus P Schlaich, John B Dixon. Am J Hypertens 2014
26
25


Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
C David Sjöström, Peter Johansson, Agata Ptaszynska, James List, Eva Johnsson. Diab Vasc Dis Res 2015
43
25

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity.
Ningning Wan, Asadur Rahman, Hirofumi Hitomi, Akira Nishiyama. Front Endocrinol (Lausanne) 2018
32
25

Autonomic nervous function, arterial stiffness and blood pressure in patients with Type I diabetes mellitus and normal urinary albumin excretion.
F J van Ittersum, M T Schram, J J van der Heijden-Spek, L M A B Van Bortel, J W F Elte, P Biemond, J A Staessen, A J M Donker, C D A Stehouwer. J Hum Hypertens 2004
29
25

Factors Responsible for Obesity-Related Hypertension.
Kyungjoon Lim, Kristy L Jackson, Yusuke Sata, Geoffrey A Head. Curr Hypertens Rep 2017
19
25

Obesity and its cardiovascular effects.
Christian Ortega-Loubon, Manuel Fernández-Molina, Gauri Singh, Ricardo Correa. Diabetes Metab Res Rev 2019
22
25

Is it time to think about the sodium glucose co-transporter 2 sympathetically?
Rosemary H Elliott, Vance B Matthews, Caroline Rudnicka, Markus P Schlaich. Nephrology (Carlton) 2016
11
25

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
H J L Heerspink, E Johnsson, I Gause-Nilsson, V A Cain, C D Sjöström. Diabetes Obes Metab 2016
115
25

Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension.
Robert J Huggett, Eleanor M Scott, Stephen G Gilbey, John B Stoker, Alan F Mackintosh, David A S G Mary. Circulation 2003
183
25

SGLT2 Inhibitors and Mechanisms of Hypertension.
Alexandros Briasoulis, Omar Al Dhaybi, George L Bakris. Curr Cardiol Rep 2018
30
25

Sympathetic nervous system and hypertension in diabetic patients.
C Vecchione, L Argenziano, L Fratta, F Pompeo, B Trimarco. Diabetes Nutr Metab 2000
9
25

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Yuliya Lytvyn, Petter Bjornstad, Jacob A Udell, Julie A Lovshin, David Z I Cherney. Circulation 2017
180
25

Predisposing factors to heart failure in diabetic nephropathy: a look at the sympathetic nervous system hyperactivity.
Klara Komici, Grazia Daniela Femminella, Claudio de Lucia, Alessandro Cannavo, Leonardo Bencivenga, Graziamaria Corbi, Dario Leosco, Nicola Ferrara, Giuseppe Rengo. Aging Clin Exp Res 2019
8
25


Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
Matthew R Weir, Andrzej Januszewicz, Richard E Gilbert, Ujjwala Vijapurkar, Irina Kline, Albert Fung, Gary Meininger. J Clin Hypertens (Greenwich) 2014
62
25

The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
Marc van Bilsen, Hitesh C Patel, Johann Bauersachs, Michael Böhm, Martin Borggrefe, Dirk Brutsaert, Andrew J S Coats, Rudolf A de Boer, Gilles W de Keulenaer, Gerasimos S Filippatos,[...]. Eur J Heart Fail 2017
53
25

Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction.
Rodica Pop-Busui, Ian Kirkwood, Helena Schmid, Victor Marinescu, Justin Schroeder, Dennis Larkin, Elina Yamada, David M Raffel, Martin J Stevens. J Am Coll Cardiol 2004
116
25

Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
Shin Kawasoe, Yukiko Maruguchi, Shoko Kajiya, Hitoshi Uenomachi, Masaaki Miyata, Mariko Kawasoe, Takuro Kubozono, Mitsuru Ohishi. BMC Pharmacol Toxicol 2017
36
25


Contribution of Autonomic Reflexes to the Hyperadrenergic State in Heart Failure.
Edgar Toschi-Dias, Maria Urbana P B Rondon, Chiara Cogliati, Nazareno Paolocci, Eleonora Tobaldini, Nicola Montano. Front Neurosci 2017
9
25

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy.
Lakshini Y Herat, Vance B Matthews, P Elizabeth Rakoczy, Revathy Carnagarin, Markus Schlaich. Int J Endocrinol 2018
9
25


Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
William L Baker, Leo F Buckley, Michael S Kelly, John D Bucheit, Eric D Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L Dixon. J Am Heart Assoc 2017
72
25

Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.
Atsunori Kashiwagi, Satoshi Yoshida, Kosei Kawamuki, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Noriko Akiyama, Yoshinori Kondo, Toshio Ogihara. Diabetol Int 2016
11
25

Diabetes and hypertension: the bad companions.
Ele Ferrannini, William C Cushman. Lancet 2012
265
25

24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
Kazuomi Kario, Kenta Okada, Mitsutoshi Kato, Masafumi Nishizawa, Tetsuro Yoshida, Tsuguyoshi Asano, Kazuaki Uchiyama, Yawara Niijima, Tomohiro Katsuya, Hidenori Urata,[...]. Circulation 2018
66
25

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Hiddo J L Heerspink, Mikhail Kosiborod, Silvio E Inzucchi, David Z I Cherney. Kidney Int 2018
108
25


Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes.
Kouichi Tamura, Hiromichi Wakui, Kengo Azushima, Kazushi Uneda, Satoshi Umemura. Hypertens Res 2016
8
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.